ASCO Quality Rapid Reaction

John Elliott from Carevive attended the ASCO Quality Conference in Chicago, where he had the opportunity to connect with partners and thought leaders in the field. The conference centered around quality improvement and its impact on patients, processes, and outcomes. John was joined by Dr. Glasnick, Carevive’s Chief Scientific Officer, and together they shared their insights from the event, particularly regarding electronic patient-reported outcomes (EPROs) and research.

Key Takeaways:
EPROs emerged as a prominent topic at ASCO Quality, with an emphasis on their implementation and integration into clinical care delivery. Dr. Glasnick highlighted the importance of utilizing data in real-time to provide clinicians with actionable insights, which Carevive excels at through its people-process-technology partnership. The discussions also delved into health equity, including considerations of differential access and tech literacy in implementing ePROs and related questionnaires. Financial toxicity was another significant aspect addressed, focusing on the challenges of selecting validated questionnaires, integrating them effectively, and leveraging the generated data for meaningful research.

Recent Episodes

Hospitals across the country are feeling the strain—too many open roles, not enough trained professionals, and a growing gap between what students learn and what the job actually demands on day one. Training is getting more expensive, timelines are stretching, and healthcare leaders are being forced to rethink how new clinicians enter the field….

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…